Market Overview

UPDATE: J.P. Morgan Lowers Alkermes' PT

Related ALKS
Top 4 NASDAQ Stocks In The Drug Delivery Industry With The Highest EPS Growth Forecast For Next 5 Years
Non-Opioid Therapeutics And Significant Pain Treatments Make For A Buy Rating
Ad Comm approaches for Fabre-Kramer's MDD med (Seeking Alpha)

According to a research report published this morning, J.P. Morgan has lowered Alkermes' (NASDAQ: ALKS) PT from $24 to $23.

In the report, J.P. Morgan said, "Post close, Alkermes announced the discontinuation of ALKS-37 (for opioid induced constipation, or OIC) after the product did not exceed management's internal threshold in Phase 2b to warrant continued development into a pivotal Phase 3 program. Overall, we view this is a modest setback to the company's pipeline, and we are not expecting a significant response in the stock. Our model had only assumed a 25% probability of success. Removing this potential call option results in our Dec 2012 PT dropping to $23 from $24."

Alkermes closed yesterday at $16.58.

Latest Ratings for ALKS

Nov 2015Leerink SwannMaintainsOutperform
Oct 2015BarclaysMaintainsOverweight
Oct 2015BarclaysMaintainsOverweight

View More Analyst Ratings for ALKS
View the Latest Analyst Ratings

Posted-In: J.P. MorganAnalyst Color Price Target Analyst Ratings


Related Articles (ALKS)

View Comments and Join the Discussion!

Get Benzinga's Newsletters